Loading company…
Mosaic Biosciences discovers and develops protein therapeutics, including therapeutic antibodies, for biopharmaceutical companies.
Mosaic Biosciences develops protein therapeutics, with a focus on therapeutic antibodies, using Phage and Yeast Display libraries. Its services span lead discovery through in vivo studies for biopharmaceutical clients. Founded in 2009 and headquartered in Boulder, US, the company raised USD 11.4 mn in a Series A round on June 14, 2022, led by Telegraph Hill Partners. Eric Furfine and Marty Stanton are co-CEOs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in